Physician profile
Laura Catherine Nall
NPI 1306308770
$2,704.25
in general payments reported to CMS, 2019-2025
25 companies · $672 in 2025
The $672 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $262 · 2023: $857 · 2024: $912 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,428 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,428.13 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $581.34 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $497.62 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $281.75 | 2023-2025 | |
| Amgen INC. | $177.60 | 2023-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $159.41 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $155.68 | 2024-2025 | Trelegy Ellipta, Shingrix |
| Organon LLC | $143.00 | 2022 | |
| Exact Sciences Corporation | $138.59 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $125.33 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.94 | 2023-2025 | |
| Daiichi Sankyo INC. | $45.64 | 2022 | |
| Astellas Pharma US INC | $43.27 | 2023-2024 | Veozah |
| Itamar Medical INC | $34.25 | 2023-2024 | Watchpatone |
| Otsuka America Pharmaceutical, INC. | $24.07 | 2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.10 | 2025 | Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $21.71 | 2023 | |
| Phadia US INC. | $21.17 | 2023 | Immunocap |
| Biohaven Pharmaceutical Holding Company LTD. | $21.14 | 2022 | |
| Dexcom, INC. | $19.52 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $19.52 | 2023 | |
| Esperion Therapeutics, INC. | $19.35 | 2024 | Nexletol |
| Sumitomo Pharma America, INC. | $18.62 | 2023 | Gemtesa |
| Silk Road Medical, INC. | $18.53 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Alnylam Pharmaceuticals INC. | $16.65 | 2025 | Givlaari |
| Boston Scientific Corporation | $13.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Nall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.